Stratagene, Rosetta Inpharmatics to Co-Develop RNA Purification System
Stratagene said this week that it has signed a joint development and license agreement with Rosetta Inpharmatics to create an automated solution for the isolation of nucleic acids from clinical samples.
Under the deal, the companies will jointly develop an instrument and a single-use consumable, which will be manufactured Stratagene for sale to its customers engaged in pharmacogenomics.
Additional terms of the agreement were not disclosed.
Bio-Rad to Buy Ciphergen's Proteomics Business for $20M, Takes Equity Stake
Bio-Rad Laboratories has agreed to purchase Ciphergen’s proteomics instrument business for approximately $20 million in cash, Ciphergen said this week. Bio-Rad is also making a $3 million equity investment in Ciphergen.
Bio-Rad will acquire Ciphergen’s proteomics products including its SELDI (surface enhanced laser desorption/ionization) technology, ProteinChip arrays, and accompanying software. Bio-Rad will manufacture, sell, and market the SELDI technology to the life sciences marketplace for applications such as biomarker discovery, characterization, and validation.
Ciphergen said that it will retain exclusive rights to the products for the diagnostics market, and that it will maintain a supply agreement with Bio-Rad to purchase SELDI instruments and consumables for the continued development of its diagnostics business. The companies will also collaborate to identify SELDI customers interested in partnering with Ciphergen to commercialize biomarker discoveries, Ciphergen said.
Following the transaction, which is expected to be approved by Ciphergen stockholders in the fourth quarter, Ciphergen will have about 40 employees dedicated to commercializing diagnostic tests, primarily in oncology, with an initial focus on ovarian and prostate cancers.
Last year, Ciphergen entered a three-year strategic alliance with Quest Diagnostics to develop and commercialize proteomic diagnostic tests, including the first for ovarian cancer. Quest purchased a 17-percent stake in the company as part of the agreement.